“Atopic dermatitis represents a diagnostic challenge, both due to the clinical heterogeneity of the disease and its complexity – a large variety of skin diseases, in fact, share signs and symptoms of atopic dermatitis – but also due to the inadequate response to therapies traditional”. Thus Ersilia Tolino, director of the Dermatology UOC and head of the atopic dermatitis and chronic inflammatory skin diseases clinic at the Fiorini hospital in Terracina (Latina), illustrates to Adnkronos the news “in the therapeutic scenario”, such as “the most recent biological drugs introduction, jak inhibitors: small molecules that block the Janus kinase enzyme, acting on both inflammation and itching”.
These drugs “have the advantage of oral administration and speed both in terms of” clinical “effectiveness and on the symptom of itching – underlines Tolino – which we know is a fundamental” symptom “in atopic dermatitis, because it causes sleep disturbances, with an important on social life and work productivity”. Based on “our experience, the intervention strategy for atopic dermatitis must be targeted and early – he adds – The treatment path must be as personalized as possible, based on the characteristics of the patient, with timely access to therapies: this, in fact, can revolutionize the management of the disease, allowing results that until recently seemed unattainable”.
Atopic dermatitis “is the most frequent chronic inflammatory skin disease in childhood – recalls Tolino – It has a prevalence of around 20%, but recent data highlight that it is also frequent in adolescence and adulthood, with a prevalence of around to approximately 10%. The diagnosis is based on the history and clinical examination, on family history of atopic diseases, on itching or on the presence of typical lesions: erythematous patches that can evolve into erythematous-papulo-vesicular plaques, which are then sites of scratching lesions, abrasions and crusts, with a tendency – he concludes – to bacterial superinfection”.
#Atopic #dermatitis #expert #Jak #inhibitors #act #inflammation #itching